Photo - Matricelf - Regenerating the future of medicine
52236

Matricelf - Regenerating the future of medicine

A platform for autologous 3D printing of tissues/organs

Israel
Market: Medicine
Stage of the project: Prototype or product is ready

Date of last change: 13.05.2021
Show contacts
0
equalizer from 2000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:
 

Idea

We are developing a platform for autologous 3D printing of tissues and organs that significantly reduce the risk of implant rejection.
Using a biopsy from the patient we develop tissues (cells and scaffold) that we can 3D print, inject or simply place where needed.
In 2019, we printed, for the first time in human history, a three-dimensional human heart from human tissue.
The company performed successful pre-clinical studies in a number of
medical conditions such as Acute Myocardial Infarction, Parkinson's Disease, Age related Macular Degeneration and more.

Current Status

Matricelf’s technology aims to completely regenerate the future of medicine.
The company completed successful pre-clinical studies in a number of
medical conditions such as acute Myocardial Infarction, Parkinson's Disease, Age related Macular Degeneration and more.

Our first indication is Spinal Cord Injury.
Each year, there are tens of thousands of new cases of traumatic Spinal Cord Injuries that usually lead to paralysis.
Considering the fact that SCI patients have no suggested treatments and are expected to spend their life in a wheelchair motivated us to further develop the technology and specifically SCI implant.
In our pre-clinical animal studies, mice treated with our implants regained their walking ability both in acute and chronic spinal cord injury models.

Problem or Opportunity

Every 30 minutes a patient dies while he/she are waiting for an organ transplantation.
Millions around the world are suffering from diseases that involves tissue damage (like diabetes, Parkinson's disease and many more).
Those diseases impose a huge economic, social and medical burden.
Many companies are developing tissue engineering technologies but they all use either cells or scaffold that are not from the same patient, leading to an immune response and organ or tissue rejection.

Solution (product or service)

Matricelf is a biotechnology company in the field of tissue engineering.
The company develops a platform for autologous (personal) 3D printing of tissues and organs that significantly reduce the risk of implant rejection.

Using a single biopsy fr om the patient we develop tissues (cells and scaffold) that we can 3D print, inject or simply place wh ere needed.

Competitors

Many companies in the world are in the area of Tissue engineering but none of them uses a complete autologous tissue like we do.
Our solution provides for the first time a completely personalized treatment where both the material and cells are derived from the patient, therefore, the implant do not provoke an immune response. Additionally, in this approach, the cells are differentiated within their final ECM 3D construct which allows mimicking the embryonic development and therefor contributing to similar structure of the engineered tissue with improve structural and functional properties.
The concept of "by demand" technology is highly innovative and have great potential.

Advantages or differentiators

Our solution provides for the first time a completely personalized treatment where both the material and cells are derived from the patient, therefore, the implant do not provoke an immune response. Additionally, in this approach, the cells are differentiated within their final ECM 3D construct which allows mimicking the embryonic development and therefor contributing to similar structure of the engineered tissue with improve structural and functional properties.
The concept of "by demand" technology is highly innovative and have great potential.

Money will be spent on

pre clinical studies in preparation to 1st human clinical trials

Team or Management

Product Video

5,00
1
2
3
4
5
1 voice
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility69
star0
Add to favorites
Delete from favorites
share
close
thumb_up1
Like
Unlike
Idea
Current Status
Market
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Invested in previous rounds, $
Business model
Money will be spent on
Offer for investor
Team or Management
Mentors & Advisors
Lead investor
Risks
Incubation/Acceleration programs accomplishment
Won the competition and other awards
Invention/Patent
Photos
Product Video